References
- Alsobhi E, Abrar MB, Abdelaal M, et al. Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study. Leuk Lymphoma 2014 Aug 4. [Epub ahead of print]
- Bhamidipati PK, Jabbour E. Frontline therapy. Chronic myeloid leukemia: from daily management to complicated issues. New York: Nova Group; 2014. pp 107–128.
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454–2465.
- Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908–3914.
- Sillaber C, Herrmann H, Bennett K, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009;39:1098–1109.
- Koskela H, Stromberg A, Richter J, et al. Tyrosine kinase inhibitor therapy induced changes in humoral immunity in patients with chronic myeloid leukemia. Blood 2011;118:740–740.
- Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010;85:387–398.
- de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 2013;122:227–238.
- Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008;14:2484–2491.
- Blake S, Hughes TP, Mayrhofer G, et al. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008;127:330–339.
- Chen JZ. Inhibition of immune responses by dasatinib may account for its different effects on neuroblastoma between in vitro and in vivo. Int J Cancer 2010;127:1249–1250.
- Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008;111:1366–1377.
- Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma 2012;53:1084–1089.
- Futosi K, Nemeth T, Pick R, et al. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012;119:4981–4991.
- Jasielec JK, Larson RA. Dasatinib-related pulmonary toxicity mimicking an atypical infection. J Clin Oncol 2014 Jun 23. [Epub ahead of print]